P980041/S051: Access AFP (on DxI 9000 Analyzer)
FDA’s recorded scope: migration of the Access AFP to the DxI 9000 Access Immunoassay Analyzer.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 9 FDA records to the applicant name BECKMAN COULTER, INC.. The collection includes 7 510(k) clearances. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 17, 2025 to Oct 20, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code NBC appears in 3 of the 9 linked filings. The collection spans 6 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P230015, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1000 Lake Hazeltine Dr., Chaska, MN, 55318, US. Recorded on K262597, decision dated Oct 20, 2026.
Test, Natriuretic Peptide; Immunoassay For Host Biomarkers Of Infection; Qualitative And Quantitative Hepatitis B Virus Antibody Assays; Hepatitis A Test (Antibody And Igm Antibody); Kit, Test, Alpha-Fetoprotein For Neural Tube Defects; Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen).
FDA’s recorded scope: migration of the Access AFP to the DxI 9000 Access Immunoassay Analyzer.
FDA’s recorded scope: Approval for the Access HBsAg, Access HBsAg Confirmatory, Access HBsAg Calibrator, Access HBsAg QCAccess HBsAg The Access HBsAg assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative detection of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] using the DxI 9000 Access Immunoassay Analyzer.The Access HBsAg assay is used for the laboratory diagnosis of acute or chronic hepatitis B virus (HBV) infection in individuals with signs and symptoms of hepatitis or at risk for hepatitis B virus infection, when used in conjunction with other serological and clinical information. The assay may also be used to screen for HBV infection in pregnant women to identify neonates who are at risk of acquiring hepatitis B during the perinatal period.The Access HBsAg assay is for use on the DxI 9000 Access Immunoassay Analyzer only.This assay has not been approved for use in the screening of blood, plasma, or tissue donors or cadaveric specimens.ACCESS HBsAg CALIBRATOR The Access HBsAg Calibrator is intended to calibrate the Access HBsAg and Access HBsAg Confirmatory assays for the in vitro qualitative detection and confirmation of hepatitis B surface antigen (HBsAg) in human serum and plasma using the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg QC The Access HBsAg QC is intended for monitoring system performance of the Access HBsAg and Access HBsAg Confirmatory assays. The Access HBsAg QC is for use on the DxI 9000 Access Immunoassay Analyzer.For additional information, refer to the Access HBsAg and Access HBsAg Confirmatory reagent Instructions for Use.ACCESS HBsAg CONFIRMATORYHepatitis B Virus Surface AntigenThe Access HBsAg Confirmatory assay is a paramagnetic particle, chemiluminescent immunoassay for the in vitro qualitative confirmation of the presence of hepatitis B surface antigen (HBsAg) in human pediatric (7 through 21 years) and adult serum and serum separator tubes or plasma [lithium heparin, lithium heparin separator tubes, dipotassium (K2) EDTA, tripotassium (K3) EDTA, sodium citrate, acid citrate dextrose (ACD), and citrate phosphate dextrose (CPD)] that have been found to be repeatedly reactive in the Access HBsAg assay using the DxI.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
MedtechLedger links 62 FDA enforcement entries through the recorded recalling firm or an exact submission number published in FDA’s recall data. 62 Class II records are represented. Each row is an enforcement entry; one recall event can cover several product entries. These counts describe this collection and do not measure a manufacturer’s safety record or an injury rate.
| Recall / product | Company | Classification | Report date | Source |
|---|---|---|---|---|
| BECKMAN COULTER, INC. | Class II | Oct 28, 2026 | FDA | |
| BECKMAN COULTER, INC. | Class II | Oct 28, 2026 | FDA | |
| BECKMAN COULTER, INC. | Class II | Oct 21, 2026 | FDA | |
| BECKMAN COULTER, INC. | Class II | Oct 21, 2026 | FDA | |
| BECKMAN COULTER, INC. | Class II | Oct 14, 2026 | FDA | |
| BECKMAN COULTER, INC. | Class II | Oct 14, 2026 | FDA |
Connections use the recorded recalling firm or the submission identifiers shown below. A shared submission connects the records; it does not establish that differently named legal applicants are interchangeable. Use the exact affected models, lots and instructions on each notice.
Search the firm’s recall recordsSource updated Nov 11, 2026. Retrieved Nov 21, 2026.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Access BNP IIK262597 | BECKMAN COULTER, INC. | 510(k) clearance | Oct 20, 2026 | FDA |
Access MeMed BVK261109 | BECKMAN COULTER, INC. | 510(k) clearance | Oct 19, 2026 | FDA |
Access NT-proBNPK262109 | BECKMAN COULTER, INC. | 510(k) clearance | Sep 21, 2026 | FDA |
Access BNP IIK252169 | BECKMAN COULTER, INC. | 510(k) clearance | Mar 24, 2026 | FDA |
Access anti-HBc IgMK254059 | BECKMAN COULTER, INC. | 510(k) clearance | Mar 13, 2026 | FDA |
Access anti-HBc TotalK253687 | BECKMAN COULTER, INC. | 510(k) clearance | Feb 19, 2026 | FDA |
Access anti-HAV IgMK251995 | BECKMAN COULTER, INC. | 510(k) clearance | Jan 27, 2026 | FDA |
Access AFP (on DxI 9000 Analyzer)P980041/S051 | BECKMAN COULTER, INC. | PMA supplement | Nov 3, 2025 | FDA |
| BECKMAN COULTER, INC. | PMA decision | Oct 17, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.